A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell non-Hodgkin Lymphoma (Glo-BNHL)

The Glo-BNHL trial is the largest platform trial in paediatric and adolescent relapsed and refractory B-cell malignancies globally. 

It has been developed in collaboration with a number of international partners, including Innovative Therapies for Children with Cancer (ITCC) and European Intergroup for Childhood NHL (EICNHL) in Europe; Children's Oncology Group (COG) and C17  in North America; and the Australia and New Zealand Children’s Haematology and Oncology Group (ANZCHOG).

The platform is aiming to test a wide range of therapies over the lifetime of the trial with the aim of finding better treatments and, ultimately, a cure for this rare paediatric cancer.

For industry partners

Find out further information on current industry partners, trial design and contractual arrangements

Also in 'Glo-BNHL'